LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
July 18, 2023 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
联拓生物合作伙伴NANOBIOTIX与杨森制药就放射治疗增敏剂NBTXR3达成 许可协议 联拓生物仍拥有在大中华区、韩国、新加坡和泰国对NBTXR3进行开发和商业化的权利
July 18, 2023 08:00 ET
|
LianBio
上海和新泽西州普林斯顿, July 18, 2023 (GLOBE NEWSWIRE) -- 联拓生物(纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日宣布其合作伙伴Nanobiotix已与强生旗下杨森（Janssen）制药子公司就一款具有研发潜力的同类首创放射治疗增敏剂NBTXR3达成许可协议。 ...
联拓生物宣布其在中国患者中开展的EXPLORER-CN III期临床研究数据已入选2023年欧洲心脏病学会年会Late-Breaking专场
July 17, 2023 07:42 ET
|
LianBio
上海和新泽西州普林斯顿, July 17, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日公布, 其在中国症状性梗阻性肥厚型心肌病（oHCM）患者中开展的EXPLORER-CN...
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
July 17, 2023 06:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
联拓生物宣布与阿斯利康在中国达成临床供应协议以评估BBP-398联合奥希替尼治疗存在EGFR突变的非小细胞肺癌患者的临床疗效
July 12, 2023 08:00 ET
|
LianBio
上海和新泽西州普林斯顿, July 12, 2023 (GLOBE NEWSWIRE) --...
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
July 12, 2023 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
联拓生物宣布CAMZYOS® (mavacamten)在新加坡获得上市批准
June 26, 2023 08:00 ET
|
LianBio
上海和新泽西州普林斯顿, June 26, 2023 (GLOBE NEWSWIRE) -- 联拓生物(纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日宣布，CAMZYOS® (mavacamten)正式获得新加坡卫生科学局的上市批准用于治疗有症状的梗阻性肥厚型心肌病（oHCM）成人患者。 ...
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
June 26, 2023 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian...
联拓生物完成在中国蠕形螨睑缘炎患者中开展的 TP-03 LIBRA III期临床试验的所有受试者入组
June 08, 2023 07:00 ET
|
LianBio
• LIBRA 临床试验旨在支持TP-03在中国的注册审批• 该临床试验的顶线结果预计将于2023年第四季度出炉 上海和新泽西州普林斯顿, June 08, 2023 (GLOBE NEWSWIRE) -- 联拓生物(纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日宣布在中国蠕形螨睑缘炎患者中开展的 TP-03 LIBRA...
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
June 08, 2023 07:00 ET
|
LianBio
• LIBRA trial designed to support registration of TP-03 in China• Topline results expected in the fourth quarter of 2023 SHANGHAI, China and PRINCETON, N.J., June 08, 2023 (GLOBE NEWSWIRE) --...